Johnson & Johnson (JNJ) news

Older JNJ news events, each with the realized, point-in-time move the market made — page 8 of 10. Back to the JNJ overview → · Full JNJ reaction history →

Latest news

Recent JNJ events, each with its measured reaction. (Page 8 of 10.)

DateHeadlineEventSource5-minTo close
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second linePress releasePR Newswire-0.18%+0.30%
DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not plannedPress releasePR Newswire-0.01%-0.56%
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myelomaPress releasePR Newswire-0.01%-0.56%
GSI, Inc. is Thrilled to Bring Cutting-Edge JD Edwards Solutions and AI-Driven Innovations to INFOCUS 2024!Press releasePR Web-0.05%-0.86%
Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary diseaPress releasePR Newswire+0.04%-0.23%
TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myelomaPress releasePR Newswire+0.04%-0.23%
Attorneys Vow to Oppose J&J’s Third Bankruptcy AttemptPress releaseBusiness Wire-0.37%-0.72%
Form 8-K JOHNSON & JOHNSON For: Sep 20SEC filing · Form 8-KSEC EDGAR-0.37%-0.72%
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc ClaimsPress releaseBusiness Wire+0.09%+0.06%
Prevent Blindness Names Howard Purcell, O.D., New England College of Optometry, as the 2025 Person of Vision Award RecipientPress releasePR Web+0.05%-0.76%
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancerPress releasePR Newswire-0.21%-0.09%
Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancerPress releasePR Newswire+0.55%+0.44%
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancerPress releasePR Newswire+0.55%+0.44%
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancerPress releasePR Newswire+0.55%+0.44%
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancerPress releasePR Newswire+0.55%+0.44%
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel diseasePress releasePR Newswire+0.02%+0.23%
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)Press releasePR Newswire-0.60%-1.18%
Form 8-K JOHNSON & JOHNSON For: Sep 10SEC filing · Form 8-KSEC EDGAR-0.60%-1.18%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancerPress releasePR Newswire+0.13%+1.07%
Johnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsPress releaseBusiness Wire+0.26%-0.48%
Form N-PX JOHNSON & JOHNSON For: Jun 30SEC filing · Form N-PXSEC EDGAR+0.08%-0.12%
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravisPress releasePR Newswire-0.45%-0.24%
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology CongressPress releasePR Newswire-0.21%-0.34%
Form 8-K JOHNSON & JOHNSON For: Aug 26SEC filing · Form 8-KSEC EDGAR-0.21%-0.34%
Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024Press releaseBusiness Wire-0.33%+0.27%
Johnson & Johnson to Acquire V-WavePress releaseBusiness Wire+0.11%+0.10%
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerPress releasePR Newswire+0.11%+0.10%
South Carolina Jury Awards $63.4 Million to Johnson & Johnson Asbestos VictimPress releaseBusiness Wire-0.21%+0.09%
Lawyers for Ovarian Cancer Victims Endorse Proposed Texas Two-Step RemedyPress releaseBusiness Wire-0.47%-1.17%
Form 13F-HR JOHNSON & JOHNSON For: Jun 30SEC filing · Form 13F-HRSEC EDGAR-0.93%-0.68%
Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of MedicinePress releasePR Newswire+0.15%+1.04%
DePuy Synthes Launches its First Active Spine Robotics and Navigation PlatformPress releasePR Newswire+1.60%+1.32%
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligiblePress releasePR Newswire-0.25%-1.25%
Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferencePress releaseBusiness Wire+0.10%+1.76%
Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanPress releaseBusiness Wire+0.36%+0.05%
FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanPress releaseBusiness Wire+0.47%+0.56%
Form 10-Q JOHNSON & JOHNSON For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.47%+0.56%
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferencePress releaseBusiness Wire-0.07%+2.30%
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionPress releasePR Newswire+0.05%-0.34%
Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanPress releaseBusiness Wire-0.10%-0.01%
Form 8-K JOHNSON & JOHNSON For: Jul 17SEC filing · Form 8-KSEC EDGAR+1.74%+3.31%
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024Press releaseBusiness Wire+1.74%+3.31%
Johnson & Johnson reports Q2 2024 resultsPress releaseBusiness Wire+1.74%+3.31%
Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26Press releaseBusiness Wire-0.52%+0.08%
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsPress releaseCanada Newswire-0.45%-0.35%
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyPress releasePR Newswire+0.29%-0.29%
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsPress releasePR Newswire+0.06%-0.32%
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurduePress releaseBusiness Wire+0.26%+0.08%
Form 11-K/A JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR+0.09%+0.42%
Form 11-K JOHNSON & JOHNSON For: Dec 31SEC filing · Form 11-KSEC EDGAR-0.10%-1.25%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground